BTG is a specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists.
Btg Plc Ord 10P is listed on the London Stock Exchange trading with ticker code BTG.L, and is part of the Medicine and Biotech Research sector. It has a market capitalisation of £323,598m, with approximately 388m shares in issue.
Btg Plc, officially known as Btg Plc Ord 10P was formed in December of 1991, making the company twenty eight years old. The company filed its latest accounts on 31st March 2015, showing a turnover of approximately 367.80 million GBX with gross profits of 253.10 million, or 0.6519 per issued share, and a pre-tax profit margin of 7.26%. Btg Plc currently has 8 directors, and has had 24 previous directors over the last 28 years. In the last set of accounts produced by Kpmg Llp, the company showed 100.20 million paid in salaries to the 986 staff (average wage of 102 thousand), with the directors receiving an average 390 thousand each. In the accounts filed in 2015, the company paid 0 in dividends.
Btg Plc is in the Medicine and Biotech Research sector.
|Summit Therapeutics Plc (SUMM.L)|
|Aggreko Plc (AGK.L)|
|Halma Plc (HLMA.L)|
|Vectura Group Plc (VEC.L)|
|Close Brothers Group Plc (CBG.L)|
|Shares in Issue||388m|
|52 Week High||0.00|
|52 Week Low||0.00|